X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA DR. DATSONS LABS SHASUN PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 123.9 -10.9 - View Chart
P/BV x 8.5 0.2 5,255.6% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
SHASUN PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs94126 75.0%   
Low Rs4631 147.6%   
Sales per share (Unadj.) Rs214.2133.0 161.0%  
Earnings per share (Unadj.) Rs5.30.2 3,519.5%  
Cash flow per share (Unadj.) Rs15.86.6 239.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3128.8 41.4%  
Shares outstanding (eoy) m56.6231.66 178.8%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x0.30.6 55.5%   
Avg P/E ratio x13.1516.1 2.5%  
P/CF ratio (eoy) x4.411.8 37.3%  
Price / Book Value ratio x1.30.6 215.7%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9582,477 159.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2,16456 3,863.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,1274,211 288.0%  
Other income Rs m22979 291.4%   
Total revenues Rs m12,3564,289 288.1%   
Gross profit Rs m1,009569 177.5%  
Depreciation Rs m594204 290.4%   
Interest Rs m415430 96.5%   
Profit before tax Rs m23013 1,808.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 16.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-736 -1,192.1%   
Profit after tax Rs m3025 6,294.2%  
Gross profit margin %8.313.5 61.6%  
Effective tax rate %-31.748.0 -65.9%   
Net profit margin %2.50.1 2,185.4%  
BALANCE SHEET DATA
Current assets Rs m6,8846,852 100.5%   
Current liabilities Rs m8,4566,711 126.0%   
Net working cap to sales %-13.03.3 -387.0%  
Current ratio x0.81.0 79.7%  
Inventory Days Days62161 38.3%  
Debtors Days Days108318 33.8%  
Net fixed assets Rs m4,9703,673 135.3%   
Share capital Rs m113317 35.8%   
"Free" reserves Rs m2,8753,761 76.4%   
Net worth Rs m3,0204,078 74.1%   
Long term debt Rs m1,8171,671 108.8%   
Total assets Rs m13,34712,633 105.7%  
Interest coverage x1.61.0 150.9%   
Debt to equity ratio x0.60.4 146.9%  
Sales to assets ratio x0.90.3 272.6%   
Return on assets %5.43.4 156.1%  
Return on equity %10.00.1 8,497.6%  
Return on capital %13.37.7 173.6%  
Exports to sales %46.422.9 202.5%   
Imports to sales %14.214.3 99.7%   
Exports (fob) Rs m5,622964 583.1%   
Imports (cif) Rs m1,728602 287.0%   
Fx inflow Rs m5,843964 606.1%   
Fx outflow Rs m2,173607 358.0%   
Net fx Rs m3,669357 1,028.2%   
CASH FLOW
From Operations Rs m3981,345 29.6%  
From Investments Rs m-1,635-2,256 72.5%  
From Financial Activity Rs m1,309-1,200 -109.1%  
Net Cashflow Rs m71-2,111 -3.4%  

Share Holding

Indian Promoters % 39.2 4.5 865.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.0 -  
FIIs % 17.6 1.4 1,303.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 94.1 42.1%  
Shareholders   20,750 20,807 99.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - CIPLA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS